Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SAN DIEGO, June 20, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.
VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than 30 years.
'We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients. This marks another milestone in our partnership with argenx and the expansion of access to Europe is another catalyst supporting our growth,' said Dr. Helen Torley, president and chief executive officer of Halozyme.
The EC decision is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. For more information on the study and its findings, please view argenx's press release issued on June 20, 2025.
The approval by the EC is valid in all 27 European Union (EU) Member States, as well as Iceland, Norway and Liechtenstein.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indication referred to in this press release. Forward-looking statements may also include statements regarding potential growth catalysts and opportunities driven by the product development and commercialization efforts of Halozyme's ENHANZE® partners. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning unexpected results or delays in the timing of the Halozyme's expected growth catalysts or in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Contacts:
Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@halozyme.com
Sydney CharltonTeneo 917-972-8407 sydney.charlton@teneo.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
17 hours ago
- Malaysian Reserve
Mowilex models environmental leadership with new Cikande factory solar panels: for every 4 liters of Mowilex paint, 1 is now powered by the sun
Key news highlights: With new solar panels at its Cikande factory, Mowilex has expanded its commitment to renewable energy, efficiency and the environment. The installation will lower the company's carbon footprint and cut grid electricity use by up to 25% per year. Mowilex earned its sixth consecutive CarbonNeutral® company certification in late 2024, and further supports Indonesia's clean energy goals with this solar project. JAKARTA, Indonesia, July 4, 2025 /PRNewswire/ — With the installation of solar panels at its Cikande factory, PT Mowilex Indonesia (Mowilex) is expanding its long-standing commitment to clean, renewable energy. Mowilex was Indonesia's first paint company to make major solar investments, demonstrating environmental leadership by first installing panels at its corporate headquarters in 2022. Over 500 solar modules now cover the roof of the main Cikande factory building. Another 252 solar modules were installed on car and motorcycle parking canopies. The system will reduce grid electricity use at the company's Cikande factory by approximately 500 kilowatt-hours (kWh) annually – and that means 1 of every 4 liters produced will be made with renewable energy. With the Cikande solar panels, Mowilex will lower its operational carbon footprint and cut non-renewable energy use by up to 25% per year. The company's new renewable energy project advances Indonesia's clean energy goals and comes just months after Mowilex earned its sixth consecutive CarbonNeutral® company certification. 'We believe in taking real action to decarbonize. This solar installation at our Cikande factory goes beyond buying offsets, and it's more than a technological upgrade. It is a reflection of our core values. As a company rooted in environmental responsibility, this initiative brings us one step closer to a cleaner future for Indonesia,' says Niko Safavi, CEO of PT Mowilex Indonesia. Through its investment in solar projects, Mowilex is actively reducing its dependence on brown energy. In contrast to brown energy, derived from fossil fuels and associated with high emissions and environmental harm, green energy represents a cleaner, renewable alternative. This strategic transition enables Mowilex to adopt a more stable, self-sufficient and environmentally responsible energy solution. The expanded use of solar also aligns with the environmental and ethical expectations of Indonesian consumers. Climate change worries 87% of Indonesians, says the global communications firm Edelman, and more than 90% of Indonesians think businesses don't do enough engagement around climate change issues. Another 90% expect CEOs to take a public stance on climate change. Mowilex embraces the opportunity to educate and deliver solutions to climate challenges through its products and practices. 'We see consumers shifting their purchasing power toward brands that actively work to mitigate climate change. Mowilex is proud to meet those market expectations,' says Safavi. 'Solar is a reliable, independent power source that contributes to our energy security and supports Indonesia's renewable energy policies. By making this long-term investment, we hope to be a model for industry and for the greater public.' Learn more about Mowilex sustainability programs and products at About PT Mowilex Indonesia PT Mowilex Indonesia (Mowilex), a subsidiary of Asia Coatings Enterprises, Pte. Ltd., is a leading producer of premium paints and coatings. Since launching the first Indonesian-made, water-based paints in 1970, the company has expanded its commitment to environmental ethics, equality, community and innovation. PT Mowilex is Indonesia's only certified carbon neutral manufacturer, producing zero and low VOC paints in modern colours, and the company regularly wins awards for its corporate social responsibility and sustainability efforts. Media contact: media@ Visit the Mowilex website for product and sustainability information.
The Sun
2 days ago
- The Sun
AweMed Series Sponsors Eczema Family Day 2025 to Support Singapore's Sensitive Skin Community
SINGAPORE - Media OutReach Newswire - 3 July 2025 - AweMed®, a skincare brand developed in collaboration with local dermatologists and paediatricians, sponsored the Eczema Family Day 2025—an annual event organised by Eczema Support Group Singapore (ESGS). The event was held on 12 April, where patients, caregivers, and healthcare professionals came together to share knowledge, foster connections, and support individuals living with eczema in Singapore. Deepening Community Engagement Through Sponsorship The brand's decision to sponsor the Eczema Family Day stems from its ongoing commitment to supporting individuals and engaging local communities with sensitive and eczema-prone skin. While the brand has been providing gentle, eczema-friendly skincare solutions for several years, this marks a new chapter in its efforts to connect directly with the eczema community. 'We've always provided support for eczema patients through our products, but we recognised the need to do more,' said a spokesperson for AweMed®. 'Increasing our visibility within the eczema community has been a long-standing goal. So, when we were approached by the main event organiser about sponsoring or participating in the annual Eczema Family Day, we were eager to get involved.' Awareness and Education on Daily Eczema Management AweMed® also invited Dr. Ellie Choi, a board-certified dermatologist at the National University Hospital, to speak at the event. Her talk, titled 'Eczema Care for All Ages: Managing It in Adults and Kids,' highlighted the chronic nature of eczema and emphasised the importance of consistent, day-to-day management. Dr. Choi also underscored the vital role that eczema support networks play in helping individuals navigate their journey. The brand's involvement also went beyond sponsorship. Team members were present to connect with attendees, offer product samples, and share practical tips on caring for sensitive and eczema-prone skin. A selected number of visitors were offered a free moisturiser for itchy skin, and all ESGS members received a 10% promotional code. Overall, the event provided a meaningful platform for AweMed® to engage directly with the community about their individual skincare concerns. Launch of a New Free Sample Initiative For those who were not present at Eczema Family Day or are not part of the ESGS, AweMed is continuing to offer free samples as part of a three-month initiative. This move is in response to a common concern expressed by many Family Day attendees—hesitation in trying new skincare due to the reactivity of their skin. As such, this initiative is designed to offer a safe, no-obligation way for users to experience the company's formulations firsthand, making its products more accessible to those newly discovering the AweMed® skincare line. This free samples programme is open to all, with no specific eligibility requirements. Samples will be distributed on a first-come, first-served basis while stocks last. Readers can also visit the brand's Instagram page for updates about an ongoing promotion. About AweMed® AweMed® is a Singapore-based skincare brand formulated specifically for sensitive and eczema-prone skin. Developed in collaboration with experienced dermatologists and paediatricians, their range includes targeted solutions such as an eczema spray for quick relief and a skin-sensitive body wash for gentle cleansing. With a commitment to safety, efficacy, and comfort, AweMed empowers individuals to 'Itch Less, Live Better, Feel Awesome.'
Malaysian Reserve
2 days ago
- Malaysian Reserve
ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe
LEATHERHEAD, England, July 3, 2025 /PRNewswire/ — MatOrtho® is proud to announce that the ReCerf® Hip Resurfacing Arthroplasty (HRA) has received its CE mark, confirming compliance with European safety and performance standards. This important milestone expands access to hip resurfacing, enabling wider availability across the UK, Europe and internationally where CE marking supports market access. 'This is more than a regulatory milestone. It represents two decades of focused effort to improve hip resurfacing through an advanced material,' said Mike Tuke, Founder of MatOrtho. 'That became a possibility with BIOLOX® delta and cooperation with CeramTec A.G. which led in stages to ReCerf – an all-ceramic resurfacing implant that is already delivering excellent results. We're proud to make this more widely available to specialist hip resurfacing surgeons, and patients who want to stay active.' ReCerf is the world's first commercially available ceramic HRA, first approved by Australia's Therapeutic Goods Administration in November 2024. Since its initial use in 2018, over 1,600 patients have received the device. Patient-reported outcomes are highly positive, and the revision rate remains very low up to six years. Made from BIOLOX® delta ceramic, ReCerf eliminates concerns historically associated with metal-on-metal bearings and preserves more of the patient's natural bone. For surgeons, it offers a familiar procedure underpinned by improved materials, and is supported by a company long recognised as the home of modern hip resurfacing. ReCerf's availability under CE marking is matched by a strong commitment to responsible adoption. MatOrtho supports structured education, careful patient selection, and ongoing clinical monitoring. A peer-led surgeon training programme is already in place to ensure safe and effective use. This achievement strengthens MatOrtho's strategic growth and reaffirms its leadership in pioneering orthopaedic solutions designed to restore normal joint function and support high level activity. For more information visit: About MatOrtho: MatOrtho (formerly Finsbury Orthopaedics) is a global leader in orthopaedic invention and innovation, committed to advancing joint replacement technologies that improve patient outcomes and set new clinical standards. Website: Photo – – View original content:
